These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer. Langer C; Soria JC Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973 [TBL] [Abstract][Full Text] [Related]
10. Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout. Favoni RE; Alama A Drug Discov Today; 2013 Jan; 18(1-2):11-24. PubMed ID: 22885521 [TBL] [Abstract][Full Text] [Related]
11. Roles of Hippo signaling in lung cancer. Wang Y; Ding W; Chen C; Niu Z; Pan M; Zhang H Indian J Cancer; 2015 Nov; 52 Suppl 1():e1-5. PubMed ID: 26548931 [TBL] [Abstract][Full Text] [Related]
12. FGFR Signaling as a Target for Lung Cancer Therapy. Desai A; Adjei AA J Thorac Oncol; 2016 Jan; 11(1):9-20. PubMed ID: 26762735 [TBL] [Abstract][Full Text] [Related]
13. New molecular targeted therapies integrated with radiation therapy in lung cancer. Provencio M; Sánchez A; Garrido P; Valcárcel F Clin Lung Cancer; 2010 Mar; 11(2):91-7. PubMed ID: 20199974 [TBL] [Abstract][Full Text] [Related]
14. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Langer CJ Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461 [TBL] [Abstract][Full Text] [Related]
15. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor. Crawford J J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580 [TBL] [Abstract][Full Text] [Related]